Navigating NIH Cuts and FDA Delays in Drug Development

House Republicans are taking a middle-of-the road approach to funding the federal health department by making deeper cuts than their Senate counterparts but granting only some of President Donald Trump’s wishes. House appropriators unveiled their version of the appropriations bill for the Health and Human Services Department on Monday, which provides the department $108 billion in discretionary funding, cutting $7 billion—or 6%—from the previous year.
Quang X. Pham, Founder, Chairman and CEO of publicly traded Cadrenal Therapeutics, discusses how such budget cuts impact his company's ability to conduct pre-clinical research on new drugs and get them through the government approval process in a timely manner. Quang speaks with Tim Stenovec and Carol Massar on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.